---
title: Final Analysis of the Phase 1b Chemotherapy And Venetoclax in Elderly Acute
  Myeloid Leukaemia Trial (CAVEAT)
date: '2025-01-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39825857/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250118170356&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Venetoclax plus azacitidine represents a key advance for older, unfit
  patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly
  AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in
  newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median
  age 71 years) were followed for a median of 41.8 months. The CAVEAT induction combined
  cytarabine and idarubicin with 5 dose levels of venetoclax (50-600 mg) for up to
  14 days. ...
disable_comments: true
---
Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median age 71 years) were followed for a median of 41.8 months. The CAVEAT induction combined cytarabine and idarubicin with 5 dose levels of venetoclax (50-600 mg) for up to 14 days. ...